Department of Chemical & Biomolecular Engineering, Sogang University, 35 Baekbeom-ro, Mapo-gu, Seoul 04107, Republic of Korea; Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey,123 Bevier Road, Piscataway, NJ 08854, USA.
Department of Chemical & Biomolecular Engineering, Sogang University, 35 Baekbeom-ro, Mapo-gu, Seoul 04107, Republic of Korea.
J Control Release. 2022 Feb;342:228-240. doi: 10.1016/j.jconrel.2022.01.012. Epub 2022 Jan 10.
RNA interference (RNAi) is being extensively investigated as a potential therapeutic strategy for cancer treatment. However, RNAi-based therapeutics have not yet been used to treat cancer because of their instability and the difficulty of microRNA (miRNA) delivery. Plasmonic nanoparticle-based RNAi nanotherapeutics have been developed for accurate and sensitive diagnosis and a strong therapeutic effect on cancers by leveraging their ease-of-use and specific properties such as photothermal conversion. In this review, recent strategies and advances in plasmonic nanoparticle-based miRNA delivery are briefly presented to facilitate the detection and treatment of several cancers. The challenges and potential opportunities afforded by the RNAi-based theragnosis field are discussed. We expect that the RNAi-integrated plasmonic nanotherapeutics discussed in this review can provide insights for the early diagnosis and effective treatment of cancer.
RNA 干扰 (RNAi) 作为癌症治疗的一种潜在治疗策略正在得到广泛研究。然而,由于 RNAi 的不稳定性和 miRNA 传递的困难,基于 RNAi 的治疗尚未用于癌症治疗。基于等离子体纳米粒子的 RNAi 纳米疗法已被开发用于通过利用其易用性和光热转换等特定特性来实现对癌症的准确和敏感诊断以及强大的治疗效果。在这篇综述中,简要介绍了基于等离子体纳米粒子的 miRNA 传递的最新策略和进展,以促进几种癌症的检测和治疗。讨论了 RNAi 治疗领域面临的挑战和潜在机遇。我们期望本文中讨论的 RNAi 整合的等离子体纳米疗法能够为癌症的早期诊断和有效治疗提供思路。